Pure Global

Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy - Trial NCT06222437

Access comprehensive clinical trial information for NCT06222437 through Pure Global AI's free database. This Phase 1 trial is sponsored by Methodist Health System and is currently Not yet recruiting. The study focuses on Polycystic Ovary Syndrome. Target enrollment is 85 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06222437
Phase 1
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06222437
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy

Study Focus

Polycystic Ovary Syndrome

Semaglutide

Interventional

drug

Sponsor & Location

Methodist Health System

Dallas, United States of America

Timeline & Enrollment

Phase 1

Jan 01, 2025

Jan 01, 2026

85 participants

Primary Outcome

Number of appropriate weekly dose,Number of days on therapy

Summary

The purpose of this study is to investigate the effect of semaglutide in women with
 Polycystic Ovarian Syndrome(PCOS ) and determine potential therapeutic benefits.

ICD-10 Classifications

Polycystic ovarian syndrome
Ovarian dysfunction, unspecified
Ovarian dysfunction
Other ovarian dysfunction
Neoplasm of uncertain or unknown behaviour: Ovary

Data Source

ClinicalTrials.gov

NCT06222437

Non-Device Trial